Lexaria Bioscience (LEXX) Exchange Rate Effect (2023 - 2026)
Lexaria Bioscience (LEXX) posted Exchange Rate Effect of $8971.0 for Q2 2026, down 56.53% sequentially from $20635.0 in Q1 2026, and down 75.87% YoY from $37173.0 in Q2 2025.
Lexaria Bioscience (LEXX) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Lexaria Bioscience has reported Exchange Rate Effect for 4 years, with the latest figure at $8971.0 in Q2 2026.
- Quarterly Exchange Rate Effect fell 75.87% year-over-year to $8971.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $34600.0 (up 158.44% YoY) and the FY2025 annual result came in at -$50519.0, down 154.94% from the prior year.
- Exchange Rate Effect declined to $8971.0 in Q2 2026 per LEXX's latest filing, from $20635.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $37173.0 in Q2 2025 and troughed at -$95255.0 in Q1 2025.
- A 4-year average of -$4224.8 and a median of $2050.0 in 2024 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 3097.82% in 2025, down 281.05% in 2025.
- Over 4 years, Exchange Rate Effect stood at $4372.0 in 2023, then sank by 172.62% to -$3175.0 in 2024, then plunged by 80.91% to -$5744.0 in 2025, then jumped by 256.18% to $8971.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $8971.0, $20635.0, and -$5744.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | 8,971.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 8,971.00 |
| May 31, 2026 | 8,971.00 |
| Feb 28, 2026 | 20,635.00 |
| Feb 28, 2026 | 20,635.00 |
| Nov 30, 2025 | -5,744.00 |
| Nov 30, 2025 | -5,744.00 |
| Aug 31, 2025 | 10,738.00 |
| Aug 31, 2025 | 10,738.00 |
| May 31, 2025 | 37,173.00 |
| May 31, 2025 | 37,173.00 |
| Feb 28, 2025 | -95,255.00 |
| Feb 28, 2025 | -95,255.00 |
| Nov 30, 2024 | -3,175.00 |
| Nov 30, 2024 | -3,175.00 |
| Aug 31, 2024 | 2,050.00 |
| Aug 31, 2024 | 2,050.00 |
| May 31, 2024 | -1,240.00 |
| May 31, 2024 | -1,240.00 |
| Feb 29, 2024 | -24,998.00 |
| Feb 29, 2024 | -24,998.00 |